WallStreetZenWallStreetZen

NASDAQ: HYPR
Hyperfine Inc Stock Forecast, Predictions & Price Target

Analyst price target for HYPR

Based on 2 analysts offering 12 month price targets for Hyperfine Inc.
Min Forecast
$1.25+54.32%
Avg Forecast
$1.43+75.93%
Max Forecast
$1.60+97.53%

Should I buy or sell HYPR stock?

Based on 2 analysts offering ratings for Hyperfine Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
2 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their HYPR stock forecasts and price targets.

HYPR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-22
lockedlocked$00.00+00.00%2023-11-30

1 of 1

Forecast return on equity

Is HYPR forecast to generate an efficient return?

Forecast return on assets

Is HYPR forecast to generate an efficient return on assets?

HYPR revenue forecast

What is HYPR's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$12.6M+14.49%
Avg 2 year Forecast
$16.2M+46.66%
Avg 3 year Forecast
$19.7M+78.66%
HYPR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HYPR revenue growth forecast

How is HYPR forecast to perform vs Medical Devices companies and vs the US market?
Company
21.08%
Industry
8.7%
Market
9.39%
HYPR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HYPR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HYPR vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
HYPR$0.81$1.43+75.93%Hold
ICCM$1.23$2.95+139.84%Strong Buy
AMIX$2.85N/AN/A
SRTS$3.25$8.00+146.15%Buy
NVNO$4.78N/AN/A

Hyperfine Stock Forecast FAQ

Is Hyperfine Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: HYPR) stock is to Hold HYPR stock.

Out of 2 analysts, 0 (0%) are recommending HYPR as a Strong Buy, 0 (0%) are recommending HYPR as a Buy, 2 (100%) are recommending HYPR as a Hold, 0 (0%) are recommending HYPR as a Sell, and 0 (0%) are recommending HYPR as a Strong Sell.

If you're new to stock investing, here's how to buy Hyperfine stock.

What is HYPR's revenue growth forecast for 2024-2026?

(NASDAQ: HYPR) Hyperfine's forecast annual revenue growth rate of 21.08% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.7%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.39%.

Hyperfine's revenue in 2024 is $11,032,000.On average, 2 Wall Street analysts forecast HYPR's revenue for 2024 to be $908,733,969, with the lowest HYPR revenue forecast at $899,380,413, and the highest HYPR revenue forecast at $918,087,525. On average, 1 Wall Street analysts forecast HYPR's revenue for 2025 to be $1,164,158,006, with the lowest HYPR revenue forecast at $1,164,158,006, and the highest HYPR revenue forecast at $1,164,158,006.

In 2026, HYPR is forecast to generate $1,418,143,034 in revenue, with the lowest revenue forecast at $1,418,143,034 and the highest revenue forecast at $1,418,143,034.

What is HYPR's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: HYPR) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of -0.02%.

What is HYPR's Price Target?

According to 2 Wall Street analysts that have issued a 1 year HYPR price target, the average HYPR price target is $1.43, with the highest HYPR stock price forecast at $1.60 and the lowest HYPR stock price forecast at $1.25.

On average, Wall Street analysts predict that Hyperfine's share price could reach $1.43 by Mar 22, 2025. The average Hyperfine stock price prediction forecasts a potential upside of 75.93% from the current HYPR share price of $0.81.

What is HYPR's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: HYPR) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.